TP53 and cancer: Importantly, we also demonstrated that the efficacy of DNA-damaging agents can be enhanced by an mTORC1 inhibitor (e.g., rapamycin) regardless of the functional status of p53, the gene most frequently mutated among all the genes examined to date in human cancer (Fig. 6E and Supplementary Fig. S3B).